Neurorehabilitation News

The FDA approved two new delivery methods of Xcopri for adults with partial-onset seizures, with the drug able to be crushed, mixed with water and administered by mouth as an oral suspension or via a nasogastric tube.

On April 11, which marks World Parkinson’s Night, the patient-led organization PD Avengers will launch Spark the Night, a global initiative dedicated to raising awareness for Parkinson’s disease.

Vagus nerve stimulation surgeries were relatively safe, with complication rates low but differing depending on the type of procedure and presence of complications, researchers reported in Brain and Spine.

A Houston-area neurohealth company announced completion of a full production test run, along with usability, feasibility design verification and electrical safety testing for its noninvasive, frequency-based deep brain stimulation device.

A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.

A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical firm for discovery, development and commercialization of small activating RNA therapeutics for rare neurodegenerative diseases.

Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.

A Minnesota-based medical technology company announced a limited commercial launch of its OneRF Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

Seizure frequency was reduced as much as 85% at 3 months in young patients with Dravet syndrome treated with a proprietary antisense oligonucleotide, according to results of phase 1/2a studies released by the manufacturer.